BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 9, 2002
View Archived Issues
Amgen Paying Roche $137.5M For European Neupogen Rights
Amgen Inc. said it will pay Roche Holding AG $137.5 million to gain control over European assets and business related to two white-cell boosters that are sold in the U.S. under the names Neupogen and Neulasta. (BioWorld Today)
Read More
GenStar, Applied Molecular Sign Collaborations With Centocor
Read More
Striatal Genes, Proteins Couple, Uncouple As Mutant Huntingtin Gene Interferes With Brain Cells
Read More
Affinium, Pfizer Enter Potential $30M Drug Discovery Alliance
Read More
Other News To Note
Read More
Immusol, Vertex Collaborating To Discover Protein Targets
Read More
U.S. Patent Disclosures
Read More